- Is chronic plaque psoriasis triggered by microbiota in the skin?2013 | Faculty of Medicine in Pilsen
- Inhibition of interleukins 12 and 23 - experience of plaque psoriasis therapy by ustekinumab2013 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- New knowledce about etanercept biological therapy of plaque psoriasis2009 | Faculty of Medicine in Hradec Králové
- New knowledce about etanercept biological therapy of plaque psoriasis2009 | First Faculty of Medicine
- Conventional treatment of chronic plaque psoriasis in the era of biological drug2013 | Publication without faculty affiliation
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial2015 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study2020 | Faculty of Medicine in Pilsen
- Elevated levels of circulating biomarkers of cell death (nucleosomes) in the patients with plaque psoriasis treated with the Goeckerman regimen2014 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Inhibition of interleukins 12 and 23- novel therapy for plaque psoriasis2010 | Faculty of Medicine in Hradec Králové
- Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic2024 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
- Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal2019 | Faculty of Medicine in Pilsen
- Individualized pharmacotherapy of plaque psoriasis with oral methotrexate: fiction or real possibility?2012 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (Clinical trial IMMerge)2020 | Faculty of Medicine in Pilsen
- Czech Recommendations for Biological Therapy of Severe Plaque Psoriasis2012 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Czech Recommendations for Biological Therapy of Severe Plaque Psoriasis2012 | Publication without faculty affiliation
- The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis +12008 | Faculty of Medicine in Hradec Králové
- The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis2008 | First Faculty of Medicine
- Clinical evaluation of the effectiveness of Dr Michaels(R) (also branded as Soratinex(R)) products in the topical treatment of patients with plaque psoriasis2016 | Second Faculty of Medicine
- Dr Michaels(R) product family (also branded as Soratinex(R)) versus Methylprednisolone aceponate - a comparative study of the effectiveness for the treatment of plaque psoriasis2016 | Second Faculty of Medicine
- Biological therapy and plaque psoriasis: contemporary practice, future perspectives Stockholm, 16.-17.6.20112011 | Faculty of Medicine in Hradec Králové
- Psoriasis vulgaris2012 | First Faculty of Medicine
- Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial2014 | Third Faculty of Medicine
- A European prospective, randomized placebo-controlled doubleblind Study on the efficacy and safety of Dr Michaels(R) (also branded as Soratinex(R)) product family for stable chronic plaque psoriasis2016 | Second Faculty of Medicine
- Selective access to the therapy of plaque psoriasis: a report on meeting in Vinna, 26.-27. Nov 20092010 | Faculty of Medicine in Hradec Králové
- Manifestation of Crohn's disease in a young woman during the course of treatment for severe form of chronic plaque psoriasis with etanercept2014 | Second Faculty of Medicine
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial2020 | Faculty of Medicine in Pilsen
- Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study2021 | Central Library of Charles University
- Znáhodněná dvojitě slepá studie léčby chronické ložiskové psoriázy (Yones, SS., Palmer, RA., Garibaldinos, TG., Hawk JLM.: Randomized Double-blind Trial of the Treatment of Chronic Plaque Psoriasis)2007 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CAIN457A2304Publication without faculty affiliation